19th Conference on Retroviruses and Opportunistic Infections (CROI 2012)

March 5-8, 2012, Seattle

CROI 2012: HIV Superinfections May Happen as Often as First Infections

Two studies of people with HIV in Rakai, Uganda, and Mombasa, Kenya, presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle show that the rate at which they acquired second, subsequent strains of HIV was about the same as the HIV incidence rate in the general population.

Read more:

CROI 2012: HIV/HCV Coinfection News from CROI 2012 [VIDEO]

Hepatitis C was a major topic at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle. Liz Highleyman from HIVandHepatitis.com spoke with Douglas Dieterich and Kenneth Sherman about advances in the field, with a focus on HIV/HCV coinfected patients.

The attention this year was apt, since an estimated one-third of people with HIV are coinfected with hepatitis C virus (HCV). Dieterich and Mark Sulkowski presented the first data on sustained virological response (SVR) using the recently approved HCV protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek) plus pegylated interferon/ribavirin in HIV/HCV coinfected patients.alt

Read more:

CROI 2012: Interactions between HCV Drug Daclatasvir and HIV Antiretrovirals Are Minimal or Manageable

The investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir (formerly BMS-790052) showed no clinically relevant effects on blood levels of 3 classes of antiretroviral agents, and changes in daclatasvir levels can likely be overcome by dose adjustment, according to a data presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.alt

Read more:

CROI 2012: New Integrase Inhibitor Dolutegravir Still Potent and Well-Tolerated at 96 Weeks

The next-generation integrase inhibitor dolutegravir maintains viral suppression and remains safe after 2 years of use, according to a small study presented Wednesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.alt

Read more:

CROI 2012: Drug Levels Predict Efficacy in PrEP Trials, Highlighting Importance of Adherence

Two analyses of PrEP studies presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle found that drug levels -- and by implication, adherence -- were strongly correlated with protection against HIV infection.

alt

Read more: